mTORC1 Inhibition Is Required for Sensitivity to PI3K p110α Inhibitors in PIK3CA -Mutant Breast Cancer
Open accessThe DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
Persistent mTORC1 signaling correlates with resistance to PI3K p110α inhibition in breast cancer, which can be overcome by inhibiting mTORC1.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Previous studies by other groups have also demonstrated the importance of mTORC1 inhibition for the effectiveness of MAPK or PI3K-pathway directed therapies in diverse tumor-types including lung, breast and melanoma39–42.”
From Combined inhibition of KRASG12C and mTORC1 kinase is synergistic in non-small cell lung cancer (2024) · cites this paper as [39]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
She, Q.-B., Chandarlapaty, S., Ye, Q., Lobo, J., Haskell, K. M., Leander, K. R., DeFeo-Jones, D., Huber, H. E., & Rosen, N. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003065 · Cited by 301
Self-citationRetractedNew response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534 · cited 1×
“Table 2 displays the breast tumor subtype, the BYL719 dose, the type of PIK3CA mutation, the amount of pS6 by H-score, the best tumor response to therapy by Response Evaluation Criteria in Solid Tumors (RECIST) criteria (28), and the tumor Fig.”
MethodmTOR Signaling in Growth Control and Disease
Laplante, M., & Sabatini, D. M. (2012) · Cell · doi:10.1016/j.cell.2012.03.017 · Cited by 8,509
The phosphoinositide 3-kinase pathway
Cantley, L. C. (2002) · Science · doi:10.1126/science.296.5573.1655 · Cited by 5,621 · cited 1×
“The phosphatidylinositol 3-kinase (PI3K) pathway, which includes the PI3K holoenzyme and the downstream effectors Akt and mammalian target of rapamycin (mTOR), is essential for cell growth, proliferation, survival, and metabolism (1, 2).”
BackgroundHigh Frequency of Mutations of the PIK3CA Gene in Human Cancers
Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A., Powell, S. M., Riggins, G. J., et al. (2004) · Science · doi:10.1126/science.1096502 · Cited by 3,437
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism
Engelman, J. A., Luo, J., & Cantley, L. C. (2006) · Nature Reviews Genetics · doi:10.1038/nrg1879 · Cited by 3,330 · cited 1×
“The phosphatidylinositol 3-kinase (PI3K) pathway, which includes the PI3K holoenzyme and the downstream effectors Akt and mammalian target of rapamycin (mTOR), is essential for cell growth, proliferation, survival, and metabolism (1, 2).”
BackgroundSelf-citationEverolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
Baselga, J., Campone, M., Piccart, M., Burris, H. A., Rugo, H. S., Sahmoud, T., Noguchi, S., Gnant, M., Pritchard, K. I., Lebrun, F., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109653 · Cited by 2,863
Self-citationTargeting PI3K signalling in cancer: opportunities, challenges and limitations
Engelman, J. A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2664 · Cited by 2,445 · cited 1×
“The PI3K family of enzymes is divided into three main classes (classes I to III), with class I being the most often implicated in human cancer (3, 4).”
BackgroundSelf-citationExploiting the PI3K/AKT Pathway for Cancer Drug Discovery
Hennessy, B. T., Smith, D. L., Ram, P. T., Lu, Y., & Mills, G. B. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1902 · Cited by 2,185 · cited 1×
“The PI3K family of enzymes is divided into three main classes (classes I to III), with class I being the most often implicated in human cancer (3, 4).”
BackgroundDebnath, J., Muthuswamy, S. K., & Brugge, J. S. (2003) · Methods · doi:10.1016/s1046-2023(03)00032-x · Cited by 1,995 · cited 2×
“IF and confocal microscopy 3D structures were fixed and stained as described (49).”
MethodTumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
Straussman, R., Morikawa, T., Shee, K., Barzily-Rokni, M., Qian, Z. R., Du, J., Davis, A., Mongare, M. M., Gould, J., Frederick, D. T., et al. (2012) · Nature · doi:10.1038/nature11183 · Cited by 1,771
Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors
Wilson, T. R., Fridlyand, J., Yan, Y., Penuel, E., Burton, L., Chan, E., Peng, J., Lin, E., Wang, Y., Sosman, J., et al. (2012) · Nature · doi:10.1038/nature11249 · Cited by 1,134
Maira, S.-M., Stauffer, F., Brueggen, J., Furet, P., Schnell, C., Fritsch, C., Brachmann, S., Chène, P., De Pover, A., Schoemaker, K., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0017 · Cited by 1,134
Tee, A. R., Manning, B. D., Roux, P. P., Cantley, L. C., & Blenis, J. (2003) · Current Biology · doi:10.1016/s0960-9822(03)00506-2 · Cited by 1,080
Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic
Kang, S., Bader, A. G., & Vogt, P. K. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408864102 · Cited by 823 · cited 1×
“PIK3CA, the gene encoding for p110a, is frequently mutated in human cancers (7, 8).”
BackgroundSun, H., Lesche, R., Li, D.-M., Liliental, J., Zhang, H., Gao, J., Gavrilova, N., Mueller, B., Liu, X., & Wu, H. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.11.6199 · Cited by 796
Folkes, A. J., Ahmadi, K., Alderton, W. K., Alix, S., Baker, S. J., Box, G., Chuckowree, I. S., Clarke, P. A., Depledge, P., Eccles, S. A., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800295d · Cited by 741
Bachelot, T., Bourgier, C., Cropet, C., Ray-Coquard, I., Ferrero, J.-M., Freyer, G., Abadie-Lacourtoisie, S., Eymard, J.-C., Debled, M., Spaëth, D., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.0708 · Cited by 703
Roux, P. P., Shahbazian, D., Vu, H., Holz, M. K., Cohen, M. S., Taunton, J., Sonenberg, N., & Blenis, J. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m700906200 · Cited by 702 · cited 1×
“The same result, although less pronounced, was obtained by measuring pS6(235/6), also modulated by the extracellular signal–regulated kinase (ERK) pathway (24) (fig.”
BackgroundBendell, J. C., Rodon, J., Burris, H. A., de Jonge, M., Verweij, J., Birle, D., Demanse, D., De Buck, S. S., Ru, Q. C., Peters, M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.1360 · Cited by 684
Self-citationWu, X., Senechal, K., Neshat, M. S., Whang, Y. E., & Sawyers, C. L. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15587 · Cited by 674
Ibrahim, Y. H., García-García, C., Serra, V., He, L., Torres-Lockhart, K., Prat, A., Anton, P., Cozar, P., Guzmán, M., Grueso, J., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0348 · Cited by 601
Self-citationLoss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR
Zhang, H., Cicchetti, G., Onda, H., Koon, H. B., Asrican, K., Bajraszewski, N., Vazquez, F., Carpenter, C. L., & Kwiatkowski, D. J. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17222 · Cited by 538
Breast Cancer–Associated PIK3CA Mutations Are Oncogenic in Mammary Epithelial Cells
Isakoff, S. J., Engelman, J. A., Irie, H. Y., Luo, J., Brachmann, S. M., Pearline, R. V., Cantley, L. C., & Brugge, J. S. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2612 · Cited by 509
Self-citationLoss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR
Zhang, H., Cicchetti, G., Onda, H., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200317222 · Cited by 482
Miller, T. W., Rexer, B. N., Garrett, J. T., & Arteaga, C. L. (2011) · Breast Cancer Research · doi:10.1186/bcr3039 · Cited by 462
Gewinner, C., Wang, Z. C., Richardson, A., Teruya-Feldstein, J., Etemadmoghadam, D., Bowtell, D., Barretina, J., Lin, W. M., Rameh, L., Salmena, L., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.06.006 · Cited by 461
Zhao, L., & Vogt, P. K. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0712169105 · Cited by 437 · cited 1×
“Class IA PI3K is a heterodimer composed of a catalytic subunit (p110) and a regulatory subunit (p85) (5, 6).”
BackgroundBrachmann, S. M., Hofmann, I., Schnell, C., Fritsch, C., Wee, S., Lane, H., Wang, S., Garcia-Echeverria, C., & Maira, S.-M. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905152106 · Cited by 303 · cited 1×
“In addition, aberrant activation of the PI3K pathway may also occur as a result of HER2 amplification (11, 12) or loss of the PTEN or INPP4B tumor suppressors (13–15).”
BackgroundTuberous sclerosis complex proteins control axon formation
Choi, Y.-J., Di Nardo, A., Kramvis, I., Meikle, L., Kwiatkowski, D. J., Sahin, M., & He, X. (2008) · Genes & Development · doi:10.1101/gad.1685008 · Cited by 258
Liu, P., Cheng, H., Santiago, S., Raeder, M., Zhang, F., Isabella, A., Yang, J., Semaan, D. J., Chen, C., Fox, E. A., et al. (2011) · Nature Medicine · doi:10.1038/nm.2402 · Cited by 257
Wallin, J. J., Edgar, K. A., Guan, J., Berry, M., Prior, W. W., Lee, L., Lesnick, J. D., Lewis, C., Nonomiya, J., Pang, J., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0446 · Cited by 229
Ilic, N., Utermark, T., Widlund, H. R., & Roberts, T. M. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1108237108 · Cited by 211
Elkabets, M., Gifford, A. M., Scheel, C., Nilsson, B., Reinhardt, F., Bray, M.-A., Carpenter, A. E., Jirström, K., Magnusson, K., Ebert, B. L., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci43757 · Cited by 201 · cited 1×
“Analysis pipelines were designed for chromogen-based immunohistological images as previously described (47).”
MethodSelf-citationBrachmann, S. M., Ueki, K., Engelman, J. A., Kahn, R. C., & Cantley, L. C. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.5.1596-1607.2005 · Cited by 179 · cited 1×
“Class IA PI3K is a heterodimer composed of a catalytic subunit (p110) and a regulatory subunit (p85) (5, 6).”
BackgroundSelf-citationA chemical-genetic screen reveals a mechanism of resistance to PI3K inhibitors in cancer
Muellner, M. K., Uras, I. Z., Gapp, B. V., Kerzendorfer, C., Smida, M., Lechtermann, H., Craig-Mueller, N., Colinge, J., Duernberger, G., & Nijman, S. M. B. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.695 · Cited by 165
Markman, B., Tabernero, J. M., Krop, I. E., Shapiro, G. I., Siu, L. L., Chen, L. C., Mita, M. M., Cuero, M. M., Stutvoet, S., Birle, D. C., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds011 · Cited by 158
Self-citationGarcía-García, C., Ibrahim, Y. H., Serra, V., Calvo, M. T., Guzmán, M., Grueso, J., Aura, C., Pérez, J., Jessen, K., Liu, Y., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2750 · Cited by 156
Self-citationTORC1 Suppression Predicts Responsiveness to RAF and MEK Inhibition in BRAF- Mutant Melanoma
Corcoran, R. B., Rothenberg, S. M., Hata, A. N., Faber, A. C., Piris, A., Nazarian, R. M., Brown, R. D., Godfrey, J. T., Winokur, D., Walsh, J., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005753 · Cited by 140
Self-citationTanaka, H., Yoshida, M., Tanimura, H., Fujii, T., Sakata, K., Tachibana, Y., Ohwada, J., Ebiike, H., Kuramoto, S., Morita, K., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2882 · Cited by 109
Burris, H. A., Rodon, J. A., Sharma, S., Herbst, R. S., Tabernero, J. M., Infante, J. R., Silva, A. M. E., Demanse, D., Hackl, W., & Baselga, J. M. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.3005 · Cited by 109
Self-citationHarbinski, F., Craig, V. J., Sanghavi, S., Jeffery, D., Liu, L., Sheppard, K. A., Wagner, S., Stamm, C., Buness, A., Chatenay-Rivauday, C., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0237 · Cited by 107
Wagner, A. J., Bendell, J. C., Dolly, S. O., Morgan, J. A., Ware, J. A., Fredrickson, J. O., Mazina, K. E., Lauchle, J., Burris, H. A., & Bono, J. S. D. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.3020 · Cited by 73
Wagner, A. J., Hoff, D., LoRusso, P. M., Tibes, R., Mazina, K. E., Ware, J. A., Yan, Y., Derynck, M. K., & Demetri, G. D. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.3501 · Cited by 66
Wall, M., Poortinga, G., Stanley, K. L., Lindemann, R. K., Bots, M., Chan, C. J., Bywater, M. J., Kinross, K. M., Astle, M. V., Waldeck, K., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0404 · Cited by 64
Juric, D., Rodon, J., Gonzalez-Angulo, A. M., Burris, H. A., Bendell, J., Berlin, J. D., Middleton, M. R., Bootle, D., Boehm, M., Schmitt, A., et al. (2012) · Cancer Research · doi:10.1158/1538-7445.am2012-ct-01 · Cited by 62
Self-citationShapiro, G., Kwak, E., Baselga, J., Rodon, J., Scheffold, C., Laird, A. D., Bedell, C., & Edelman, G. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.3500 · Cited by 45
Self-citationJuric, D., Rodon, J. A., Gonzalez-Angulo, A., Burris, H. A., Bendell, J. C., Berlin, J., Middleton, M. R., Bootle, D., Boehm, M., Schmitt, A., et al. (2012) · Cancer Research · Cited by 39
Self-citationJuric, D., Argiles, G., Burris, H., Gonzalez-Angulo, A., Saura, C., Quadt, C., Douglas, M., Demanse, D., De Buck, S., & Baselga, J. (2012) · Cancer Research · doi:10.1158/0008-5472.sabcs12-p6-10-07 · Cited by 31
Self-citationAbstract 3749: Single agent activity of PIK3CA inhibitor BYL719 in a broad cancer cell line panel
Huang, A., Fritsch, C. M., Wilson, C. J., Reddy, A., Liu, M., Lehár, J., Quadt, C., Hofmann, F., & Schlegel, R. (2012) · Cancer Research · doi:10.1158/1538-7445.am2012-3749 · Cited by 28 · cited 3×
“At 1 mM, BYL719 blocks p110a without affecting the other p110 isoforms (20).”
BackgroundSelf-citationHoff, D., LoRusso, P. M., Tibes, R., Shapiro, G. I., Weiss, G. J., Ware, J. A., Fredrickson, J., Mazina, K. E., Levy, G. G., & Wagner, A. J. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.2541 · Cited by 20
Research works printed but not linked: 1
- Kim PS, Von Ahsen O, Schmitz A, Schatz C, Magonova K, Lee T, Harvie G, Barham R, Leesman G, Kuller A, Lin F, Gong H, Krahn T, Singh S. Pathway profiling of signal transduction proteins in paired tumor and adjacent normal tissues obtained from breast cancer patients. Cancer Res. 2010;70 [Google Scholar]
Cited by
The PI3K Pathway in Human Disease
Fruman, D. A., Chiu, H., Hopkins, B. D., Bagrodia, S., Cantley, L. C., & Abraham, R. T. (2017) · Cell · doi:10.1016/j.cell.2017.07.029 · Cited by 2,749
“Persistent mTORC1 activity in PIK3CA mutant breast cancer cell lines was responsible for resistance to the p110a-selective inhibitor alpelisib (BYL719; Table S1) and was reversed by combination with the mTORC1 inhibitor everolimus (Elkabets et al., 2013).”
BackgroundPI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
Glaviano, A., Foo, A. S. C., Lam, H. Y., Yap, K. C. H., Jacot, W., Jones, R. H., Eng, H., Nair, M. G., Makvandi, P., Geoerger, B., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01827-6 · Cited by 2,138
PI3K and cancer: lessons, challenges and opportunities
Fruman, D. A., & Rommel, C. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4204 · Cited by 1,709
Targeting PI3K in cancer: mechanisms and advances in clinical trials
Yang, J., Nie, J., Ma, X., Wei, Y., Peng, Y., & Wei, X. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0954-x · Cited by 1,520
“BYL719 (alpelisib), an oral selective PI3Kα isoform inhibitor, exhibited dose-dependent antitumor activity in tumor xenograft models, particularly models with mutated or amplified PIK3CA, highlighting the potential antitumor activity of alpelisib in patients with PIK3CA-altered tumors [151, 152].”
BackgroundArdito, F., Giuliani, M., Perrone, D., Troiano, G., & Muzio, L. L. (2017) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2017.3036 · Cited by 1,336
“Signaling networks in which protein kinases operate are highly complex, but we believe that understanding the regulatory functions of kinases may be a valid means to identify more effective therapies against cancer (146,147).”
Metadata
- Authors
- Elkabets, M., Vora, S., Juric, D., Morse, N., Mino-Kenudson, M., Muranen, T., Tao, J., Campos, A. B., Rodon, J., Ibrahim, Y. H., Serra, V., Rodrik-Outmezguine, V., Hazra, S., Singh, S., Kim, P., Quadt, C., Liu, M., Huang, A., Rosen, N., Engelman, J. A., Scaltriti, M., & Baselga, J.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Massachusetts General Hospital (US)
- Harvard University (US)
- Vall d'Hebron Institute of Oncology (ES)
- Prometheus Therapeutics & Diagnostics, 9410 Carroll Park Drive, San Diego, CA 92121, USA.
- Novartis (Switzerland) (CH)
- Oncology Translational Medicine, Novartis Institutes for BioMedical Research, Cambridge, MA 02139, USA.
- Human Oncology & Pathogenesis Program and Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 20, New York, NY 10065, USA.
- Corresponding author
- Scaltriti, Maurizio
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2013-07-31
- Volume
- 5
- Issue
- 196
- Pages
- 196ra99-196ra99
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- PMC
- PMC3935768
- OpenAlex
- W2153096480
- Cited by
- 332
- References
- 50
- Citations by year
- 2026: 10 · 2025: 12 · 2024: 33 · 2023: 18 · 2022: 13 · 2021: 34 · 2020: 33 · 2019: 32 · 2018: 16 · 2017: 27 · 2016: 34 · 2015: 34 · 2014: 29 · 2013: 7
- FWCI
- 15.54
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- Funders
- National Cancer Institute (K99CA180221, R01CA137008)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Keywords
- mTORC1 inhibition, PIK3CA mutation, breast cancer, alpelisib, everolimus, drug resistance, Akt phosphorylation, insulin-like growth factor I, neuregulin-1, combination therapy, mTOR signaling
- MeSH terms
- Everolimus, Mechanistic Target of Rapamycin Complex 1, Phosphoinositide-3 Kinase Inhibitors, Adult, Animals, Breast Neoplasms, Female, Humans, Insulin-Like Growth Factor I, Middle Aged, Mutation, Treatment Outcome, Drug Resistance, Neoplasm, Phosphatidylinositol 3-Kinases, Sirolimus, Inhibitory Concentration 50, Neuregulin-1, Ribosomal Protein S6, Cell Line, Tumor, Multiprotein Complexes, Protein Kinase Inhibitors, Mice, Class I Phosphatidylinositol 3-Kinases, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.